Drug information provided by: Merative, Micromedex®
Daunorubicin and cytarabine injection is used to treat therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC).
Daunorubicin and cytarabine liposome interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by doxorubicin and cytarabine liposome, other unwanted side effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is to be given only by or under the supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2023
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
A generous benefactor has pledged $1 million and challenged us to raise an additional $250,000. Help us reach our goal!